


Neuraminidase-IN-10

Cat. No.:	HY-151103
CAS No.:	2685786-29-0
Molecular Formula:	C ₂₆ H ₃₄ N ₂ O ₅ S
Molecular Weight:	486.62
Target:	Influenza Virus
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Neuraminidase-IN-10 is a potent neuraminidase (NA) inhibitor with anti-influenza activity. Neuraminidase-IN-10 is against H1N1, H5N1, and H5N8 with IC ₅₀ values of 2.6 nM, 5.1 nM, and 1.65 nM, respectively ^[1] .								
In Vitro	<p>Neuraminidase-IN-10 displays promising anti-influenza virus activity with EC₅₀ value of 7.28 and 0.71 μM for H5N1 and H5N8, respectively in CEFs. Neuraminidase-IN-10 displays anti-influenza virus activity with EC₅₀ values of 0.04 ± 0.04 and 28.70 ± 1.61 μM, respectively in MDCK Cells^[1].</p> <p>Metabolic stability is an important indicator for the assessment of drug candidates. Neuraminidase-IN-10 exhibits a T_{1/2} (min), CL_{int(mic)} (μL/min/kg), CL_{int (liver)} (mL/min/kg) and remaining (T=60 min)(%) values of 120.5 min, 11.5 μL/min/kg, 10.4 mL/min/kg and 73.8 mins, respectively^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								
In Vivo	<p>Neuraminidase-IN-10 (0.156 mM-10 mM; injected into the eggs) showed good protection against both H5N1 and H5N8 strains in a dose-dependent manner in a chicken embryonated egg model^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>SPF Chicken Embryonated Egg^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0.156 mM; 0.625 mM; 2.5 mM; 10 mM</td> </tr> <tr> <td>Administration:</td> <td>Injected into the egg</td> </tr> <tr> <td>Result:</td> <td> <p>were not as effective as OSC in this infection model, but also exhibited a certain therapeutic effect.</p> <p>The survival rates of Neuraminidase-IN-10 (H5N1: 100 and 40%, respectively; H5N8: 100 and 100%, respectively) at 2.5 mM and 10 mM^[1].</p> </td> </tr> </table>	Animal Model:	SPF Chicken Embryonated Egg ^[1]	Dosage:	0.156 mM; 0.625 mM; 2.5 mM; 10 mM	Administration:	Injected into the egg	Result:	<p>were not as effective as OSC in this infection model, but also exhibited a certain therapeutic effect.</p> <p>The survival rates of Neuraminidase-IN-10 (H5N1: 100 and 40%, respectively; H5N8: 100 and 100%, respectively) at 2.5 mM and 10 mM^[1].</p>
Animal Model:	SPF Chicken Embryonated Egg ^[1]								
Dosage:	0.156 mM; 0.625 mM; 2.5 mM; 10 mM								
Administration:	Injected into the egg								
Result:	<p>were not as effective as OSC in this infection model, but also exhibited a certain therapeutic effect.</p> <p>The survival rates of Neuraminidase-IN-10 (H5N1: 100 and 40%, respectively; H5N8: 100 and 100%, respectively) at 2.5 mM and 10 mM^[1].</p>								

REFERENCES

[1]. Han Ju, et al. Iterative Optimization and Structure-Activity Relationship Studies of Oseltamivir Amino Derivatives as Potent and Selective Neuraminidase Inhibitors via Targeting 150-Cavity. J Med Chem. 2022 Aug 8. doi: 10.1021/acs.jmedchem.1c01970.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA